PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

HAMA, Joanne

nder the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless a contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO

Application Number 10/706,691 Filing Date November 12, 2003 First Named Inventor Andrew Robert Davids Art Unit 1632

Attorney Docket Number 674582-2001

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

QE JC/48

STENT 8

(Use as many sheets as necessary)

Sheet 1 of 2

Examiner	Cita	December 11 miles	U. S. PATENT D		T 6	
Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (of Assum)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	_	Number-Kind Code			- iguius repedi	
	1	US-			1	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	_	US-				
	_	US-	 			
		US-		· · · · · · · · · · · · · · · · · · ·		

Examiner Name

Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relavant Passages Or Relevant Figures Appear	Т
		Country Code ³ "Number ⁴ " Kind Code ⁵ (If known)	MM-DD-YYYY			To
	1	EP 1 033 401 A3	04-21-2004	Genset		
	2	WO 01 54477 A	08-02-2001	Tang, et al.		
	3	WO 02 40671 A	05-23-2002	Baughn, et al.		
	4	WO 02 34783 A	05-02-2002	Warren, et al.		

Examiner	 Date
Signature	Considered

Examiner
Signature

EXAMINER: Initial if reterence considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: Initial if reterence considered, whether or not citation to applicant. Applicant's unique citation designation number (optional). See Citation with next communication to applicant. Applicant's unique citation designation number (optional). See Citation with next content of MIPPO Standard ST3, For "EXAMPLE": Intitle I reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in Sectionance and not updated. The property of the form with next communication is splicant. Applicates subject citation designation number (opcount). See Arch Cades of USEP 0 Property of the form with next communication of the property of the pro Translation is attached.

Transaction is actual value.

18 bits collection of Information is required by 37 CFR 197 and 1.99. The information is required to obtain or retain a benefit by the public which is to file (and by the USPYO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to last 2 has, no to complete, including gathering, preparing, and summitting the completed application from the USPYO. Then will vary depending upon the individual case, nor comments on the amount of time you require to complete this form ander suggestions for reducing this bushon, should be sent to the Chel Information Officer, U.S. Petent and Tademann Chief., P.O. Box 1430, Massarding, N. 2231-4450. D. ON OT SENDN FEES OR COMPLETE PORRIST OT INS ADDRESS. SENDING. TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Juliani	101011011111111111111111111111111111111			Application Number	10/706,691	
			CLOSURE	Filing Date	November 12, 2003	
STATEMENT BY APPLICANT				First Named Inventor	Andrew Robert Davids	
	(Use as many sha	ate se n	acassan/l	Art Unit	1632	
	(occ to many one			Examiner Name	HAMA, Joanne	
Sheet	2	of	2	Attorney Docket Number	674582-2001	

Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Edwards J.B.D.M: "Sequence Tag and encoded human protein" retrieved from	T ²
5	Edwards J.B.D.M: "Sequence Tag and encoded human protein" retrieved from	
	HTTP://www.EBI.AC.UK, Database accession no. BD511416 XP002259339 8	27/0
6	Tang, et al.: Isolated polypeptides for treatment of diseases, diagnostics, raising antibodies and research use." XP 002259341 10/12/01	
7	Sugano, et al., "NEDO human cDNA Sequencing project" Database accession no. AK098396; XP 002259340 7/15/02	
8	International Search report for Ares Trading S.A. dated May 12, 2003; PCT/GB03/01851 filed April 30, 2003	

	7	Tang, et al.: Isolated polypeptides for treatment of diseases, diagnostics, raising antibodies and research use." XP 002259341 10/12/01 Sugano, et al., "NEDO human cDNA Sequencing project" Database accession no. AK098396; XP 002259340 7/15/02 International Search report for Ares Trading S.A. dated May 12, 2003;

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considering, include copy of this form with nat communication to applicant include copy of the form with nat communication to applicant this collection of information is required by 37 CFR 18. If the information is required to obtain or retain a benefit by the public which is to file include by the USPTO to process) an application. Confederalisty is governed by 35 U.S. C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including pathwrity, preparing and submitting the compreted application from the USPTO. Time will vary deprending upon the included case. Any comments on this pathwrity, preparing and submitting that compreted application from the USPTO. Time will vary deprending upon the included case. Any comments on this pathwrity, prepared to the community of the USPTO. The comments of the USPTO. So the Comments of the USPTO. The comments of the USPTO. The comments of the USPTO. So the Comments of the USPTO. The comments of the USPTO. The USPTO.